RE: Opinion24 Feb 2021 20:15
I reckon Vlad is a single-minded character, a scientist but not without business acumen and who has very clear goals.
He might have half an eye on the SP from time to time, but why bother really, if the results are good and the company moves from pre-clinical to clinical, the SP will take care of itself.
He's secured funding, the pipeline is outstanding, they have some incredible partnerships and the science looks very, very promising indeed.
At 0.5M shares, like many of you I've suffered over the last weeks but I'm not selling these. Captain Hindsight is always right and of course I wish I'd sold at 14p so I could buy back in cheaper but that wasn't the way it went.
I've always had a good feeling about the Lilly deal (not very scientific, I know...!) and I still think that's more likely than not.